FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D	D.C. 20549	
---------------	------------	--

STATEMENT OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPR	OVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol TransMedics Group, Inc. [ TMDX ]									licable) tor		Person(s) to Issuer  10% Owner  Other (specify		
(Last) (First) (Middle) C/O TRANSMEDICS GROUP, INC.						3. Date of Earliest Transaction (Month/Day/Year) 10/03/2022									Officer (give title below)  VP of O		below)		
200 MIN	IUTEMAN	ROAD			4 1	f Ame	ndmei	nt Date (	of Origin	al File	ad (Month/D	av/Vear)	6	Individual or	loint/Grour	n Filin	n (Check Ar	nlicable	
(Street)	ER M	Α	01810			Ame	ilairici	ni, Daie v	of Original Filed (Month/Day/Year)					Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)											1 0130	11				
		Tab	le I - N	on-Deriv	/ative	Sec	curit	ies Ac	quired	l, Di	sposed o	of, or Be	neficia	lly Owne	d				
Date			2. Transa Date (Month/D		Ex f) if a	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3,		d (A) or r. 3, 4 and	5) Securiti Benefic Owned	5. Amount of Securities Beneficially Owned Following		n: Direct	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock				10/03/	/03/2022				M <sup>(1)</sup>		784	A	\$2.2	1 1	,555	D			
Common Stock 10				10/03/	3/2022				M <sup>(1)</sup>		2,216	A	\$0.2	8 3	,771	D			
Common Stock 10/0				10/03/	2022				S <sup>(1)</sup>		2,320	D	\$41.93	3(2) 1	2) 1,451		D		
Common Stock 10/03/2			2022	022		S <sup>(1)</sup>		680	D	\$42.63	771			D					
		Т	able II								oosed of converti			y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Execution if any (Month/I	med	4. Transaction Code (Instr. 8)		5. Number of		6. Date Exerci Expiration Dat (Month/Day/Ye		sable and te	7. Title an Amount o Securities Underlyin Derivative (Instr. 3 au	d of s g e Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ow For Dire or I (I) (	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares	1					
Stock Option (Right to Buy)	\$2.21	10/03/2022			<b>M</b> <sup>(1)</sup>			784	(4)		06/22/2027	Common Stock	784	\$0.00	2,000	)	D		
Stock Option (Right to Buy)	\$0.28	10/03/2022			M <sup>(1)</sup>			2,216	(4)		05/29/2023	Common Stock	2,216	\$0.00	12,273	3	D		

## **Explanation of Responses:**

- 1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$41.51 to \$42.50, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$42.52 to \$42.95, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 4. The option is fully vested.

## Remarks:

/s/ Stephen Gordon, as attorney-in-fact

\*\* Signature of Reporting Person

10/04/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.